Market Overview

Ryan & Maniskas, LLP Announces Investigation of Ambit Biosciences Corporation


WAYNE, Pa., Oct. 1, 2014 /PRNewswire/ --  Ryan & Maniskas, LLP is investigating potential claims against the board of directors of Ambit Biosciences Corporation ("Ambit" or the "Company") (NASDAQ: AMBI) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to Daiichi Sankyo Company, Ltd. in a transaction valued at approximately $315 million.

Ryan & Maniskas, LLP.

If you own shares of Ambit and would like to learn more about this class action or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit:  You may also email Mr. Maniskas at

Under the terms of the agreement, shareholders of Ambit would receive $15.00 in cash for each share of Ambit they own.

Our investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Ambit for not acting in the Company's shareholders' best interests in connection with the sale process. 

Ryan & Maniskas, LLP is a national shareholder litigation firm.  Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.  To learn more about the class action process, please visit:

Ryan & Maniskas, LLP
Richard A. Maniskas, Esquire
995 Old Eagle School Rd., Suite 311
Wayne, PA 19087

Logo -

SOURCE Ryan & Maniskas, LLP

View Comments and Join the Discussion!